Gubra

478.00 DKK

-2.29 %

Less than 1K followers

GUBRA

NASDAQ Copenhagen

Biotechnology & Pharmaceuticals

Health Care

Overview

Financials & Estimates

Ownership

Investor consensus

Compare

-2.29 %

+6.70 %

+20.40 %

-10.15 %

-23.40 %

-30.52 %

+334.55 %

Gubra is a pharmaceutical company. The company's operations are focused on the early stages of drug development. They primarily conduct research and development in the area of metabolic and fibrotic diseases. The company's product portfolio includes several brands and drugs, and the operations are conducted on a global level, with the largest presence in North America and the Nordic region. The headquarters are located in Hørsholm, Denmark.

Market cap

7.82B DKK

Turnover

30.51M DKK

Revenue

265.74M

EBIT %

-18.82 %

P/E

Dividend yield-%

12.8 %

Coverage

Disclaimer

Michael Friis, Philip Coombes

Latest research

Latest analysis report

Released: 2025-03-17

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar

27/2

2026

Annual report '25

All

Research

Webcasts

Press releases

ShowingAll content types

Regulatory press release16 hours ago

Reporting of transactions made by persons discharging managerial responsibilities and persons closely associated with them in Gubra A/S' shares

Gubra

Analyst Commentyesterday by

Philip Coombes

Gubra - New partnership with Camurus to develop a long-acting treatment for hypoparathyroidism

Gubra has entered into an exclusive collaboration and license agreement with Camurus to develop a long-acting treatment for hypoparathyroidism, combining Gubra’s parathyroid hormone (PTH) analogue (discovered via its AI-enabled streaMLine platform) with Camurus’ FluidCrystal® sustained-release technology. The aim is to reduce injection frequency and improve disease control versus current once-daily PTH therapies, addressing a clear unmet need in this rare endocrine disorder.

Gubra

Press releaseyesterday

Gubra and Camurus Enter into a Collaboration and License Agreement to Develop a Long-acting Treatment for Hypoparathyroidism

Gubra

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account

Followings and notifications on followed companies

Analyst comments and recommendations

Stock comparison tool & other popular tools

Create account

Regulatory press release12/8/2025, 7:00 AM

Boehringer Ingelheim advances next generation triple-agonist peptide for the treatment of obesity into mid-stage development

Gubra

Regulatory press release11/10/2025, 8:23 PM

Reporting of transactions made by persons discharging managerial responsibilities and persons closely associated with them in Gubra A/S' shares

Gubra

Regulatory press release11/10/2025, 4:29 PM

Reporting of transactions made by persons discharging managerial responsibilities and persons closely associated with them in Gubra A/S' shares

Gubra

Regulatory press release11/7/2025, 5:03 PM

Reporting of transactions made by persons discharging managerial responsibilities and persons closely associated with them in Gubra A/S' shares

Gubra

Regulatory press release11/7/2025, 6:30 AM

Reporting of transactions made by persons discharging managerial responsibilities and persons closely associated with them in Gubra A/S' shares

Gubra

Regulatory press release7/10/2025, 8:07 PM

Reporting of transactions made by persons discharging managerial responsibilities and persons closely associated with them in Gubra A/S' shares

Gubra

Regulatory press release6/30/2025, 7:51 AM

Claus Thestrup

Gubra: Trading statement Q1-2025

Gubra

Regulatory press release5/9/2025, 5:30 AM

Trading statement Q1-2025: A landmark deal for GUBamy

Gubra

Gubra

478.00 DKK

-2.29 %

Coverage

Latest research

Revenue and EBIT-%

EPS and dividend

Financial calendar

Reporting of transactions made by persons discharging managerial responsibilities and persons closely associated with them in Gubra A/S' shares

Gubra - New partnership with Camurus to develop a long-acting treatment for hypoparathyroidism

Gubra and Camurus Enter into a Collaboration and License Agreement to Develop a Long-acting Treatment for Hypoparathyroidism

Join Inderes community

Inderes account

Boehringer Ingelheim advances next generation triple-agonist peptide for the treatment of obesity into mid-stage development

Reporting of transactions made by persons discharging managerial responsibilities and persons closely associated with them in Gubra A/S' shares

Reporting of transactions made by persons discharging managerial responsibilities and persons closely associated with them in Gubra A/S' shares

Reporting of transactions made by persons discharging managerial responsibilities and persons closely associated with them in Gubra A/S' shares

Trading statement Q3-2025: Expanding our R&D activities

Record earnings for Gubra; revised outlook for the CRO business

Gubra Announces Completion of Solar & Battery Park

Interim report H1 2025: Group revenue and earnings record-high

Record quarter for Gubra, but revised outlook for the CRO business

Markus Rohrwild appointed new CEO of Gubra in a planned succession process

Reporting of transactions made by persons discharging managerial responsibilities and persons closely associated with them in Gubra A/S' shares

Reporting of transactions made by persons discharging managerial responsibilities and persons closely associated with them in Gubra A/S' shares

Gubra shares are traded ex-dividend

COURSE OF GUBRA A/S' EXTRAORDINARY GENERAL MEETING REGARDING EXTRAORDINARY DIVIDEND

NOTICE TO CONVENE EXTRAORDINARY GENERAL MEETING REGARDING EXTRAORDINARY DIVIDEND

Gubra: Trading statement Q1-2025

Trading statement Q1-2025: A landmark deal for GUBamy